Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Underwent Allogenic Stem Cell Transplantation (HSCT)Tariq Kewan, Amer M. Zeidan, Mikkael A. Sekeres et al.|Blood|2023Cited by 1
Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA)Tariq Kewan, Amer M. Zeidan, Jan Philipp Bewersdorf et al.|Blood|2023Cited by 0
Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective AnalysisJan Philipp Bewersdorf, Amer M. Zeidan, Tariq Kewan et al.|Blood|2023Cited by 0